Poly Medicure Ltd
Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices.[1]
- Market Cap ₹ 14,391 Cr.
- Current Price ₹ 1,420
- High / Low ₹ 2,318 / 1,182
- Stock P/E 44.0
- Book Value ₹ 306
- Dividend Yield 0.25 %
- ROCE 14.0 %
- ROE 11.2 %
- Face Value ₹ 5.00
Pros
- Company has delivered good profit growth of 19.4% CAGR over last 5 years
Cons
- Debtor days have increased from 83.8 to 103 days.
- Working capital days have increased from 126 days to 249 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 390 | 411 | 454 | 519 | 610 | 687 | 785 | 922 | 1,115 | 1,375 | 1,669 | 1,875 | |
| 304 | 323 | 361 | 397 | 479 | 520 | 569 | 707 | 847 | 1,014 | 1,214 | 1,433 | |
| Operating Profit | 86 | 88 | 93 | 122 | 131 | 166 | 216 | 215 | 267 | 361 | 455 | 442 |
| OPM % | 22% | 21% | 21% | 23% | 22% | 24% | 28% | 23% | 24% | 26% | 27% | 24% |
| 28 | 8 | 14 | 16 | 20 | 21 | 22 | 40 | 38 | 60 | 94 | 119 | |
| Interest | 10 | 10 | 8 | 12 | 14 | 20 | 11 | 6 | 11 | 14 | 14 | 18 |
| Depreciation | 19 | 21 | 24 | 29 | 37 | 41 | 48 | 54 | 57 | 63 | 83 | 116 |
| Profit before tax | 85 | 65 | 75 | 97 | 100 | 126 | 180 | 195 | 237 | 344 | 453 | 427 |
| Tax % | 27% | 27% | 27% | 27% | 35% | 24% | 25% | 25% | 25% | 25% | 25% | 25% |
| 62 | 48 | 55 | 71 | 65 | 96 | 136 | 147 | 179 | 258 | 339 | 321 | |
| EPS in Rs | 7.07 | 5.47 | 6.25 | 8.00 | 7.41 | 10.86 | 14.17 | 15.28 | 18.69 | 26.91 | 33.41 | 31.78 |
| Dividend Payout % | 18% | 27% | 40% | 25% | 27% | 18% | 18% | 16% | 16% | 11% | 10% | 11% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 19% |
| 3 Years: | 19% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 19% |
| 3 Years: | 24% |
| TTM: | -2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 7% |
| 3 Years: | 14% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 14% |
| 3 Years: | 14% |
| Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 | 51 | 51 |
| Reserves | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 | 2,715 | 3,055 |
| 79 | 82 | 101 | 133 | 161 | 207 | 137 | 127 | 149 | 174 | 180 | 354 | |
| 89 | 76 | 85 | 94 | 112 | 126 | 121 | 163 | 187 | 215 | 246 | 459 | |
| Total Liabilities | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 | 3,919 |
| 165 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 | 1,084 | 1,702 | |
| CWIP | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 | 101 | 91 |
| Investments | 4 | 4 | 3 | 17 | 8 | 25 | 354 | 346 | 126 | 167 | 1,077 | 755 |
| 185 | 187 | 227 | 264 | 321 | 354 | 422 | 499 | 738 | 748 | 930 | 1,371 | |
| Total Assets | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 | 3,919 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63 | 63 | 56 | 75 | 106 | 131 | 119 | 123 | 191 | 266 | 240 | 246 | |
| -59 | -31 | -56 | -88 | -101 | -109 | -436 | -85 | -179 | -241 | -1,194 | -225 | |
| -6 | -31 | -0 | 16 | -5 | -21 | 317 | -35 | -13 | -20 | 951 | 20 | |
| Net Cash Flow | -2 | 1 | 0 | 3 | 1 | 1 | 0 | 3 | -1 | 5 | -3 | 41 |
| Free Cash Flow | 13 | 31 | -0 | -7 | 31 | 25 | 24 | -31 | -48 | -9 | -89 | -59 |
| CFO/OP | 101% | 88% | 79% | 80% | 102% | 100% | 75% | 80% | 93% | 94% | 73% | 79% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59 | 74 | 77 | 79 | 77 | 68 | 72 | 82 | 77 | 72 | 76 | 103 |
| Inventory Days | 148 | 114 | 194 | 161 | 186 | 241 | 217 | 218 | 237 | 205 | 233 | 265 |
| Days Payable | 101 | 76 | 131 | 96 | 123 | 142 | 111 | 115 | 105 | 89 | 71 | 75 |
| Cash Conversion Cycle | 106 | 111 | 140 | 144 | 139 | 166 | 179 | 185 | 209 | 188 | 239 | 294 |
| Working Capital Days | 25 | 35 | 55 | 71 | 56 | 42 | 74 | 81 | 69 | 54 | 74 | 249 |
| ROCE % | 30% | 26% | 24% | 26% | 22% | 25% | 22% | 17% | 18% | 24% | 20% | 14% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Countries Exported To Count ・Standalone data |
|
||||||||||
| Number of SKUs / Product Categories Count |
|||||||||||
| Patents Granted (Cumulative) Count |
|||||||||||
| Domestic Revenue Contribution % |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Intimation Of Analyst/Investor Meet
2d - Company informed about the Analyst/Investor Meet to be held on 08th June, 2026.
-
Intimation For The Analyst/Investors Meet
2 Jun - Poly Medicure schedules one-on-one investor meetings on 3-4 June 2026 with multiple funds.
-
Announcement under Regulation 30 (LODR)-Change in Management
1 Jun - Mr. Indranil Mukherjee appointed CEO-Asia Pacific and India Business, effective June 1, 2026.
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 29 May
-
Investors Call Scheduled To Be Held On 27 May, 2026 Is Cancelled - Updates On Call
26 May - Poly Medicure cancelled one-on-one investor meeting with Trust AMC on 27 May 2026 at Faridabad plant.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
Concalls
-
May 2026Transcript PPT REC
-
May 2026TranscriptAI SummaryPPT
-
Mar 2026Transcript PPT REC
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT REC
-
Oct 2025Transcript PPT
-
Sep 2025Transcript PPT
-
Sep 2025Transcript PPT REC
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024TranscriptPPTREC
-
Sep 2024TranscriptAI SummaryPPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptPPT
-
Nov 2023TranscriptPPT
-
Aug 2023TranscriptPPT
-
May 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Jul 2021TranscriptPPT
-
May 2021Transcript PPT
-
Feb 2021TranscriptAI SummaryPPT
Product Portfolio:[1]
PML is a medical devices company
with a product portfolio comprised of
200+ SKUs of medical devices across
12 specialties including therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and
blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others.